Related Experiment Video
Updated: Jun 21, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
FKBP5 polymorphisms and antidepressant response in geriatric depression
Jane E Sarginson1, Laura C Lazzeroni1, Heather S Ryan1
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Summary
Genetic variations in FKBP5 do not predict antidepressant treatment outcomes in geriatric patients. This study found no significant association between FKBP5 polymorphisms and clinical efficacy for paroxetine or mirtazapine.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Geriatric Psychiatry
Background:
- Genetic variations in FKBP5 have been inconsistently linked to antidepressant treatment response.
- FKBP5 is implicated in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis sensitivity.
Purpose of the Study:
- To investigate the association between two FKBP5 single nucleotide polymorphisms (rs1360780 and rs3800373) and antidepressant treatment outcomes in geriatric patients.
- To determine if FKBP5 genetic variants predict efficacy of paroxetine and mirtazapine in this population.
Main Methods:
- A double-blind randomized comparison trial involving 246 geriatric patients treated for 8 weeks.
- Analysis of FKBP5 polymorphisms (rs1360780 and rs3800373) in relation to clinical outcomes, including Hamilton Depression Rating Scale scores and time to remission or response.
Main Results:
- No significant associations were found between the tested FKBP5 genetic variants and clinical outcomes in geriatric patients.
- FKBP5 polymorphisms did not predict mean Hamilton Depression Rating Scale scores or time to remission or response to paroxetine or mirtazapine.
Conclusions:
- FKBP5 genetic variation is unlikely to be a major determinant of antidepressant treatment outcomes in geriatric patients.
- These findings suggest that FKBP5 genotype may not be a reliable predictor for antidepressant efficacy in this specific patient group.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...